Utilization and denials of skin and tissue substitutes in Medicare Authors: Elsa Zhang, Yue Gao, Joshua M Liao Published: 2026 Introduction In 2026, the Center for Medicare and Medicaid Services implemented the Wasteful and Inappropriate Service Reduction Model (WISeR). The model seeks to address wasteful spending through artificial intelligence-enabled prior authorization, identifying skin and tissue substitutes as a key target.1 Skin and tissue substitutes are products commonly used for chronic wounds, such as diabetic foot ulcers, despite ongoing debate regarding their clinical effectiveness and appropriate utilization.2,3 Despite mixed evidence supporting clinical use, spending on these products has risen sharply, increasing from $256 million in 2019 to $10 billion in 2024, alongside claims denials due in part to growing concerns about fraud and abuse.2,4,5 Fraud and abuse may be in part reflected through frequent inappropriate billing, and subsequently, higher denial rates for claims. Unlike commercial insurers, which often use prior authorization to restrict inappropriate billing, Traditional Medicare determines denials through National and Local Coverage Determinations that have historically yielded lower initial denial rates. As spending and utilization of skin and tissue substitutes have rapidly increased, changing denial patterns may signal inappropriate use and motivate policy efforts in enacting novel technologies in claims review. Despite these concerns and the emergence of WISeR, long-term trends in use and denial rates for skin and tissue substitutes remain poorly characterized. Methods We analyzed 2010-2024 Medicare Part B fee-for-service claims nationwide. These data included information on submitted and denied services, accepted and denied charge amounts, and provider specialty. Cells with fewer than 11 claims were suppressed in accordance with federal privacy requirements, and our analysis focused on clinicians and claims with available, unsuppressed cells for all variables. Sensitivity analyses imputed suppressed cells assuming 5 and 10 services per cell, representing mid-point and upper bound values under suppression rules. The dataset excluded Outpatient Prospective Payment System claims. Skin and tissue substitute services were identified using 130 Current Procedural Terminology codes approved for reimbursement under Medicare Local Coverage Determinations.1 We calculated service volume, reimbursement, and denial rates overall and annually, and evaluated patterns by specialty. This analysis was exempted from Institutional Review Board due to the aggregate, publicly available data. Results Our analysis included 21 411 282 skin and tissue substitute services submitted between 2010 and 2024. Over this period, use increased approximately 2.7-fold from 786 418 to 2 158 286 submitted services. Denial rates fluctuated, with an overall denial rate of 20.8% across 2010-2024, ranging from 15.4% in 2020 to 40.9% in 2015. Correspondingly, potential payments from denied services increased from $13.1 million in 2010 to $409.0 million in 2024 (Figure 1). Trends of skin and tissue substitutes service counts from 2010 to 2024. Across the study period, skin and tissue substitutes were most frequently used by podiatry (44.0%), nurse practitioners (16.3%), dermatology (7.0%), general surgery (6.9%), and plastic and reconstructive surgery (5.6%). Among these groups, general surgery had the highest denial rate at 29.4% corresponding to $151.5 million in potential payments, followed by plastic and reconstructive surgery (28.4%, $118.6 million), podiatry (17.5%, $516.4 million), nurse practitioner (16.7%, $466.3 million), and dermatology ($14.6%, $76.9 million). From 2010 to 2024, over three quarters of submitted counts and charges were suppressed (76.9%) while the vast majority of denied counts and charges (94.2%) were suppressed. Of all suppressed rows in the dataset, podiatry accounted for 26.7%, followed by plastic and reconstructive surgery (17.6%), general surgery (12.9%), nurse practitioners (4.6%), and vascular surgery (4.5%). Sensitivity analyses imputing 5 and 10 services per cell yielded 32 602 298 and 35 188 533 submitted services, with overall denial rates of 21.2% and 21.4%, respectively (Appendix). Discussion Over fifteen years, use of skin and tissue substitutes increased substantially among Medicare patients, driven disproportionately among a small subset of providers and specialties and corresponding to high denial rates. Our analysis aligns with the Center for Medicare and Medicaid Services’ concerns regarding wasteful spending and prior evidence of rapid growth in skin and tissue substitute use.1,2,5 In particular, while prior research described growth in overall utilization trends and specialty-level variation, we found high denial rates for submitted claims, suggesting that a substantial portion of submitted claims may not meet Medicare coverage criteria.4,5 Though the situations could arise from noncompliance with coverage policies or documentation deficiencies rather than fraud, our data underscores the need for continued efforts aimed at promoting appropriate utilization.3 Such efforts are already underway with WISeR and with the Center for Medicare and Medicaid's nationwide standardization of skin substitute prices, which is expected to substantially reduce spending.1,2 However, these approaches also face limitations, including restricted implementation, potential administrative burden, and remaining uncertainty in appropriate use. In turn, policymakers could pursue further monitoring, program integrity efforts, and evaluation of policies to further mitigate fraud and abuse. Consistent with these policy considerations, our analysis provides additional evidence on clinician-level utilization patterns. We observed high rates of suppression among counts and charges for skin and tissue substitutes, indicating that most clinicians used skin and tissue products infrequently (delivering fewer than 11 claims over the course of a year). In turn, the fact that only the minority of clinicians had unsuppressed data suggests that a small group of clinicians provides a large number of services while most clinicians provide few services. This pattern may reflect mixed and evolving evidence on the clinical effectiveness of skin and tissue substitutes, leading to selective adoption by clinicians, alongside financial incentives that may encourage more intensive use among a subset of providers.2,3 Future work is necessary to better understand the drivers of this distinction between high- and low-volume adopter clinicians. Nonetheless, the concentration observed in our analysis suggests that current policy efforts, including programs like WISeR, as well as any future policy efforts could include targeted efforts to address service provision among high-volume clinicians rather than broader, program-wide interventions. Study limitations included lack of access to clinical data for determining appropriateness as well as the inability to directly measure fraud vs other forms of administrative error or claims nonadherence, particularly amid evolving coverage policies over a 15-year period. Nonetheless, by characterizing long-term trends in use and denial for skin and tissue substitutes, this analysis underscores the importance and potential impact of WISeR and similar programs aimed at balancing clinical benefits with program integrity. Supplementary Material Contributor Information Elsa Zhang, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Program on Policy Evaluation and Learning, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Yue Gao, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Joshua M Liao, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Program on Policy Evaluation and Learning, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Author contributions J.M.L. and Y.G. had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: JML. Acquisition, analysis, and interpretation of data: E.Z., Y.G., J.M.L. Drafting of the manuscript: E.Z., J.M.L. Critical revision of the manuscript for important intellectual content: Y.G., J.M.L. Statistical analysis: Y.G. Administrative, technical, or material support: E.Z., Y.G., J.M.L. Study supervision: J.M.L. Supplementary material Supplementary material is available at Health Affairs Scholar online. Funding The authors report no sources of support, including grants, funding, or other assistance, whether from public or private sources. Data availability This study used publicly available, aggregate Medicare Physician/Supplier Procedure Summary data released by the Centers for Medicare & Medicaid Services. The data can be accessed through the Center for Medicare and Medicaid Services website and contain no individual-level or identifiable patient information. Disclaimer We have no disclaimers to disclose. This manuscript represents original work that has not been previously published, posted as a preprint, or disseminated through abstracts, posters, or conference presentations, and is not under consideration at another journal. All contributors are listed as authors, and no compensation was received by non-authors. Notes Associated Data Supplementary Materials Data Availability Statement This study used publicly available, aggregate Medicare Physician/Supplier Procedure Summary data released by the Centers for Medicare & Medicaid Services. The data can be accessed through the Center for Medicare and Medicaid Services website and contain no individual-level or identifiable patient information.